Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cornelius Kortsik"'
Autor:
Monika Serke, Petra Neuser, Niels Reinmuth, Michael Thomas, Philipp A. Schnabel, Alexander Reuss, Martin Wolf, Cornelius Kortsik, Jürgen Fischer, Piotr Czapiewski, Stefan Andreas, Matthias Villalobos
Publikováno v:
Oncology Letters
The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung
Autor:
Stephan Budweiser, Tobias Gaska, Martin Reck, Harald Schäfer, Andrea Schueler, Wolfgang M. Brueckl, Eckardt Laack, Stefan Krüger, Justyna Rawluk, Konrad Kokowski, Christopher M. Hoffmann, Cornelius Kortsik
Publikováno v:
Journal of Clinical Oncology. 38:e21636-e21636
e21636 Background: Afatinib is an irreversible ErbB family blocker, which is approved for the treatment of advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. Here we report the final results of the prospective non-in
Autor:
Jürgen Fischer, Monika Serke, Martin Wolf, Alexander Reuss, Niels Reinmuth, Cornelius Kortsik, Philipp A. Schnabel, Petra Neuser, Michael Thomas, Piotr Czapiewski, Matthias Villalobos, Stefan Andreas
Publikováno v:
Medical oncology (Northwood, London, England). 35(7)
Prior studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. The aim
Autor:
Martin Schuler, Beatrice Wehler, Kurt Werner Schmid, Martin Sebastian, J. Wohlschläger, Stefan Kasper, Daniela Westerwick, Birgit Gaschler-Markefski, Arno Schad, Gerd Munzert, Martin Werner, Karl Worm, Alicia Morresi-Hauf, Joachim von Pawel, Saskia Ting, Frank Breitenbuecher, Cornelius Kortsik
Background: Polo like kinase 1 (PLK1) is frequently upregulated in tumors and is thus viewed as a promising therapeutic target in various cancers. Several PLK1 inhibitors have recently been developed and clinically tested in solid cancers, albeit wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88233e25fdcedd25c30c20e3ea4c6154
https://www.ncbi.nlm.nih.gov/pubmed/28628916
https://www.ncbi.nlm.nih.gov/pubmed/28628916
Autor:
S. Bohnet, David F. Heigener, Martin Reck, Cornelius Kortsik, Joachim von Pawel, M.v. Eiff, W. Koester, Philipp A. Schnabel, K.M. Deppermann, Michael Thomas, Juergen R. Fischer
Publikováno v:
Lung Cancer. 84:62-66
Background Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotin
Autor:
Peter Klein, Thomas Muley, Ines Moldenhauer, Thomas Kuhnt, Wilfried Eberhardt, Esther Herpel, Michael Meister, Sandra Gottschling, Philipp A. Schnabel, J.R. Fischer, Roland Penzel, Cornelius Kortsik, David F. Heigener, Claus-Henning Köhne, Helge Bischoff, Michael Thomas
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 77(1)
Background In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows response rates of ≥70% and a significant prolongation of progres
Autor:
Walburga Engel-Riedel, Christian Schumann, Cornelius Kortsik, Wolfgang Schuette, Monika Serke, Claus-Peter Schneider, Martin Kohlhaeufl, Sylke Nagel, Gert Hoeffken, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 31:8013-8013
8013 Background: Pemetrexed (P) and bevacizumab (B) are efficacious drugs for treatment of non-squamous NSCLC. In this trial the benefit of combining PB with carboplatin (C) was investigated in elderly patients (pts) ≥ 65 years with NSCLC. Methods:
Autor:
Gábor Veres, T Nees, Urs Riede, C Darda, P Rahner, M Schubert, Cornelius Kortsik, K Frenzer-Welle, András Kiss, R. Lamers, Nikolaus Freudenberg
Publikováno v:
Virchows Archiv : an international journal of pathology. 428(3)
We investigated the reaction of the cellular immune system of liver and blood in the C57BL/6 mouse to a metastasizing Lewis lung carcinoma. The cellular immune system of the liver consists of mature and immature macrophages, B-cells, T-cells includin
Autor:
Michael Thomas, Juergen R. Fischer, Philipp A. Schnabel, Christian Grah, Stefan Andreas, Dirk Behringer, Niels Reinmuth, R. Heine, Alexander Reuss, Monika Serke, Christian Witt, Cornelius Kortsik, M. Schroeder, Jens Kollmeier, Ernst Müller, M. Schenk, Martin Wolf, Thomas Acker, L. J. Müller, M. von Eiff
Publikováno v:
Journal of Clinical Oncology. 29:7504-7504
7504 Background: Combining EGFR kinase inhibition (E) with an anti-VEGF strategy (B) showed promising activity (RR 20%; PFS 6.2 months) in recurrent NS-NSCLC (J Clin Oncol (2005) 23: 2544). To asse...
Autor:
K. Schott von Römer, Nick Thatcher, Gabriele Koschel, Cornelius Kortsik, J. Mezger, Lothar R. Pilz, Christian Manegold
Publikováno v:
Journal of Clinical Oncology. 25:7648-7648
7648 Background: Treatment efficacy and toxicity of the three studies have been presented at ASCO (2006, Abstract # 7035). Patients (pts) received gemcitabine or docetaxel either as single agents in different schedules and doses or as a platinum free